NCT06400472
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with one of the following cancers (depending on which part of the trial you join): ovarian cancer (including primary peritoneal or fallopian tube cancer), endometrial cancer, cervical cancer, non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, or colorectal cancer
- For the later stages of the trial, eligibility is more specific — focused on low grade serous ovarian cancer, cervical cancer, non-small cell lung cancer, and triple negative breast cancer (confirm with trial site which stage applies to you)
Who may not be able to join:
- You have cancer that has spread to the brain or spinal cord in a way that is not controlled
- You have a history of cancer spreading to the membranes surrounding the brain or spinal cord
- You currently have an active infection (bacterial, viral, fungal, or parasitic) that is not under control
- You have a known eye condition affecting the cornea, or have previously had a cornea transplant
- You still have significant side effects remaining from a previous cancer treatment
- You have serious heart or cardiovascular disease
- You have an abnormal heart rhythm reading on an ECG that is above a certain threshold (confirm with trial site)
- You have a history of lung inflammation or scarring of the lung tissue
- You are currently pregnant, breastfeeding, or planning to breastfeed during the study or within 30 days of your last dose of the study treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156; Phase 1a: To determine the RP2D or optimal dose of LY4170156 with bevacizumab; Phase 1a: To determine the RP2D or optimal dose of LY4170156 with carboplatin; Phase 1a: To determine the RP2D or optimal dose of LY4170156 with pembrolizumab; Phase 1b: To assess the antitumor activity of LY4170156 Monotherapy: Overall response rate (ORR); Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.